Press releases

GynTect soon available in China: – oncgnostics grants exclusive license for GynTect to the Chinese SINOPHARM subsidiary CJMT – approval for the Chinese market planned

,
Dr. Xia Xiaokai and Dr. Alfred Hansel, chairman of oncgnostics GmbH. In the background: Yang Xiaoming, chairman of CNBG, Wolfgang Tiefensee, Thuringia's Minister for economics, Dr. Michael Brandkamp, chairman of the High-Tech-Gründerfonds sowie Peter Haug, oncgnostics. photo: Christoph Worsch

Jena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) for marketing GynTect® in China, Hongkong and Macao. The contract comprising four milestones rules the approval of GynTect® at the Chinese Food and Drug Agency […]

Read more
/by

oncgnostics presents extended version of its cervical cancer diagnostics test GynTect at MEDICA

Jena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of cervical cancer – at the world-leading trade fair Medica. Between 14th and 17th of November 2016 the epigenetics experts will explain the advantages of the […]

Read more
/by

Early detection of cervical cancer: „GynTect 2.0“- wider range of application by using a greater variety of patient samples

New version of cervical cancer triage test GynTect available

Jena, September 20th, 2016 – GynTect, a molecular diagnostic test developed by the biotech company oncgnostics, allows fast and reliable diagnostics of cervical cancer and the corresponding precancerous stages. The test has been revised now, offering an extension of its application, as compared to the first version. This extended version of GynTect is now available […]

Read more
/by

Oncgnostics GmbH cooperates with SAYRE Therapeutics in India

oncgnostics cooperates with Sayre

Bangalore/Jena, 28.04.2016 – The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics. GynTect is a molecular test, which allows timely clarification, if a patient with abnormal Pap test finding and/or a positive test for the cancer-causing human papillomaviruses […]

Read more
/by

Greiner Bio-One starts international marketing of the cervical cancer triage test GynTect

Jena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH, who has developed and produces the GynTect® test, prior to Medica 2015. […]

Read more
/by

Fast and reliable results in cancer diagnostics: Biotech startup oncgnostics receives CE mark for cervical cancer test „GynTect“

Jena (Germany), September 18th, 2015 – A new test for use in cervical cancer screening is CE-IVD marked in whole Europe with immediate effect. It may quickly yield reliable test results, which will allow to identify more cancer cases early and thus to yield better therapy outcome. Developed by the biotech startup oncgnostics (www.oncgnostics.com) GynTect […]

Read more
/by